Releases - Orexo

View:
 

Found press releases

 

Abstral EU success continues. Orexo receives sales milestone of 3.3 MEUR.

5/25/2012 4:00 AM EST
Uppsala, Sweden – May 25, 2012 - Orexo AB (STO: ORX) announced today that accumulated sales of Abstral has surpassed 65 MEUR, which was faster than earlier anticipated and results in a 3.3 MEUR milestone payment from ProStrakan.

Abstral is the leading new fast acting fentanyl product in Europe and this position has been further strengthened during the first four months of 2012. Abstral has continued to win market...

Orexo presents new focus and plans for commercial expansion – accelerated develo...

5/3/2012 7:50 AM EST
Uppsala, May 3, 2012 – At today’s Capital Markets Day, Orexo announces that – following a successful restructuring – Orexo is now sharpening focus further on development and commercializing own products based on its proprietary drug-delivery technologies applied to well-known substances. The switch from relying solely on partners to commercialize the Company’s innovations entails substantially higher control of the...

Interim report, January-March 2012

4/27/2012 2:00 AM EST
Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2011.

OREXO’S REVENUES FROM ABSTRAL® CONTINUE TO INCREASE

During the period

· Net revenues amounted to MSEK 83.6 (41.5).
· Abstral royalty revenues increased by 39 percent to MSEK 19.4 (14.0).
· Earnings after tax were MSEK -16.2 (-39.2).Cash flow from operating activities was a...

Reminder: Invitation to Capital Markets Day 2012

4/26/2012 5:36 AM EST
Uppsala, Sweden, April 26, 2012 – We have the pleasure of inviting analysts, investors and media to Orexo’s Capital Markets Day 2012 to be held in Stockholm on May 3, 2012.
Date:           Thursday May 3, 2012
Time:          2 p.m. to 5 p.m.
Venue:       Sveavägen 20, 9th floor, Stockholm. (Please note the change to Stockholm)
RSVP:         registration ASAP via email to  

Agenda and...

Report from Orexo AB’s Annual General Meeting, 11 April 2012

4/11/2012 12:30 PM EST
The Annual General Meeting approved the income statement and the balance sheet for the parent company, as well as of the consolidated income statement and the consolidated balance sheet for the financial year 2011. It was resolved that there shall be no dividend for 2011 and that the results of the company shall be carried forward.

The meeting resolved to re-elect Raymond Hill, Staffan Lindstrand och Michael Shalmi...

Invitation Capital Markets Day May 3, 2012

4/4/2012 10:30 AM EST
Uppsala, Sweden, April 4, 2012 – We have the pleasure of inviting analysts, investors and media to Orexo’s Capital Markets Day 2012 to be held in Stockholm on May 3, 2012.

Date:          Thursday May 3, 2012
Time:          2 p.m. to 5 p.m.
Venue:        Sveavägen 20, 9th floor, Stockholm. Please note the change of venue!
RSVP:         by April 20, registration via email to  

Agenda and...

Orexo Capital Markets Day May 3, 2012

3/27/2012 4:00 AM EST
”Save the date”
Orexo will conduct a Capital Markets Day on Thursday, May 3, 2012. The event, that addresses in particular analysts, investors and media, starts at 2:00pm and will be held at the company premises at Virdings allé 32 A in Uppsala.

Detailed program will be available closer to the event at www.orexo.com, where registration also can be made. Limited number of seats.

Welcome!

For further...

Notice of Annual General Meeting of Orexo

3/12/2012 5:00 AM EST
The shareholders in Orexo AB (publ) are summoned to the annual general meeting, to be held on Wednesday 11 April 2012, at 4.00 pm in Orexos facilities at Virdings allé 32A, in Uppsala, Sweden.
Participation, etc

Shareholders who wish to participate in the meeting must be recorded in the share register maintained by Euroclear Sweden AB on Tuesday 3 April 2012, and notify Orexo of their intention to attend the...

Orexo AB focuses its business and reduces costs

3/6/2012 5:00 AM EST
Uppsala, Sweden - March 6, 2012 - Orexo AB is focusing its development activities to the three proprietary programs OX219, OX51 and OX27. The total requirement for resources will thereby be reduced with up to 35 full time employees.
The personnel reduction, which will have full effect in 2013, is expected to lower the costs by a total of SEK 30 million annually. Negotiations with trade union representatives will...

Interim Report January-December 2011

1/31/2012 2:31 AM EST
Unless otherwise stated in this report, all data refers to the group. Figures in parentheses are for the corresponding periods in 2010.

POSITIVE DEVELOPMENT IN ABSTRAL® SALES AND OREXO’S PROPRIETARY PROGRAMS WHILE THE OX-CLI AND OX-ESI PROJECTS ARE ABORTED

During the year

· Net revenues amounted to 199.6 MSEK (210.5).
· The loss after tax was MSEK -392.0 (-89.2).
· Impairment of acquired development related to...

Orexo

Orexo AB (publ) is a pharmaceutical company, focusing on development of new, patented drugs by combining well-documented substances with innovative technologies, and the development of new treatments for respiratory and ...

View more


  CONTACT